Trevi Therapeutics (TRVI) to Release Earnings on Tuesday

Trevi Therapeutics (NASDAQ:TRVI) is projected to release its earnings data before the market opens on Tuesday, March 18th. Analysts expect Trevi Therapeutics to post earnings of ($0.12) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Trevi Therapeutics Stock Up 7.3 %

TRVI stock opened at $6.75 on Friday. Trevi Therapeutics has a twelve month low of $2.30 and a twelve month high of $7.39. The company has a market cap of $518.85 million, a PE ratio of -15.34 and a beta of 0.90. The business’s 50-day simple moving average is $4.35 and its 200 day simple moving average is $3.63.

Insider Activity

In related news, insider Farrell Simon sold 81,313 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $6.75, for a total value of $548,862.75. Following the completion of the transaction, the insider now owns 76,900 shares in the company, valued at $519,075. The trade was a 51.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 24.37% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on TRVI. Raymond James raised Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $9.00 to $29.00 in a research report on Monday, March 10th. D. Boral Capital reaffirmed a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a report on Friday, March 7th. HC Wainwright lifted their price objective on Trevi Therapeutics from $7.50 to $12.50 and gave the company a “buy” rating in a report on Monday, March 10th. Oppenheimer lifted their price objective on Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, March 11th. Finally, Needham & Company LLC lifted their price objective on Trevi Therapeutics from $8.00 to $25.00 and gave the company a “buy” rating in a report on Monday, March 10th. Seven investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $15.94.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.